OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
RUBX55

Rubex International for Plastic and Acrylic Manufacturing S A E

Commodity ChemicalsVerified

Rubex maintains a debt-to-equity ratio of 0.54, indicating a relatively conservative capital structure with manageable leverage. The company's liquidity position is assessed as medium, with a current ratio of 1.61, suggesting it can cover short-term obligations but with limited surplus. However, the company's operating cash flow is negative at -3.46 million EGP, which raises concerns about its ability to fund operations without external financing. Profitability metrics show a return on equity of 1.94% and a return on assets of 1.06%, both below the typical thresholds for strong performance in the Commodity Chemicals industry. The company's net income of 2.79 million EGP is modest relative to its total assets of 261.94 million EGP, indicating limited efficiency in converting assets into profit. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which increases exposure to regional economic fluctuations. There is no information on revenue by geographic region, but the lack of segment diversification suggests a high concentration risk. Looking ahead, the company's growth trajectory is uncertain, as there are no disclosed revenue growth projections for the current or next fiscal year. The capital expenditure of -2.71 million EGP indicates a reduction in investment, which may signal a strategic shift or financial constraint. The company's free cash flow of 2.99 million EGP provides some flexibility, but it is not sufficient to offset the negative operating cash flow. The risk assessment highlights liquidity concerns, with net cash being negative after subtracting total debt. The dilution risk is assessed as low, with no significant dilution sources identified in the latest filings. However, the company's reliance on external financing to fund operations could increase if cash flow remains negative. Recent filings and transcripts do not provide additional insights into the company's strategic direction or operational performance. The absence of detailed disclosures on future plans or market expansion efforts limits the ability to assess long-term growth potential.

30-day price · RUBX+2.50 (+28.7%)
Low$8.60High$13.90Close$11.21As of14 May, 00:00 UTC
Profile
CompanyRubex International for Plastic and Acrylic Manufacturing S A E
TickerRUBX.CA
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. Rubex International for Plastic and Acrylic Manufacturing S A E produces and distributes plastic and acrylic products, generating revenue primarily through the sale of these materials to industrial and consumer markets.

Classification. Rubex is classified under the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry, with a confidence level of 0.92 based on verified market data.

Rubex maintains a debt-to-equity ratio of 0.54, indicating a relatively conservative capital structure with manageable leverage. The company's liquidity position is assessed as medium, with a current ratio of 1.61, suggesting it can cover short-term obligations but with limited surplus. However, the company's operating cash flow is negative at -3.46 million EGP, which raises concerns about its ability to fund operations without external financing. Profitability metrics show a return on equity of 1.94% and a return on assets of 1.06%, both below the typical thresholds for strong performance in the Commodity Chemicals industry. The company's net income of 2.79 million EGP is modest relative to its total assets of 261.94 million EGP, indicating limited efficiency in converting assets into profit. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which increases exposure to regional economic fluctuations. There is no information on revenue by geographic region, but the lack of segment diversification suggests a high concentration risk. Looking ahead, the company's growth trajectory is uncertain, as there are no disclosed revenue growth projections for the current or next fiscal year. The capital expenditure of -2.71 million EGP indicates a reduction in investment, which may signal a strategic shift or financial constraint. The company's free cash flow of 2.99 million EGP provides some flexibility, but it is not sufficient to offset the negative operating cash flow. The risk assessment highlights liquidity concerns, with net cash being negative after subtracting total debt. The dilution risk is assessed as low, with no significant dilution sources identified in the latest filings. However, the company's reliance on external financing to fund operations could increase if cash flow remains negative. Recent filings and transcripts do not provide additional insights into the company's strategic direction or operational performance. The absence of detailed disclosures on future plans or market expansion efforts limits the ability to assess long-term growth potential.
Key takeaways
  • Rubex has a conservative capital structure with a debt-to-equity ratio of 0.54, but its liquidity position is only medium due to a current ratio of 1.61.
  • The company's profitability is weak, with a return on equity of 1.94% and a return on assets of 1.06%, below industry benchmarks.
  • Revenue is concentrated in a single business segment, increasing exposure to market-specific risks.
  • The company's growth trajectory is unclear, with no disclosed revenue growth projections and a reduction in capital expenditures.
  • Liquidity risk is elevated due to negative operating cash flow and a negative net cash position after debt.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyEGP
Revenue$57.6M
Gross profit$14.5M
Operating income$5.6M
Net income$2.8M
R&D
SG&A
D&A
SBC
Operating cash flow-$3.5M
CapEx-$2.7M
Free cash flow$3.0M
Total assets$261.9M
Total liabilities$118.7M
Total equity$143.2M
Cash & equivalents$9.4M
Long-term debt$77.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$200.1M$10.6M$688.6k$628.4k
FY-3$216.9M$7.4M$526.2k-$4.2M
FY-2$220.4M$6.7M-$8.1M-$446.8k
FY-1$329.4M$39.0M$18.7M$18.4M
FY0$388.6M$26.1M$4.2M-$15.6M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$263.1M$150.5M$13.4M
FY-3$261.0M$151.0M$15.2M
FY-2$248.1M$142.9M$12.7M
FY-1$350.2M$159.1M$7.4M
FY0$372.1M$162.3M$7.1M
PeriodOCFCapExFCFSBC
FY-4$5.5M-$11.7M$628.4k
FY-3-$563.7k-$15.3M-$4.2M
FY-2$17.9M-$3.9M-$446.8k
FY-1-$17.6M-$12.1M$18.4M
FY0-$2.8M-$32.4M-$15.6M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$57.6M$5.6M$2.8M$3.0M
FQ-6$75.5M$14.1M$8.4M$8.8M
FQ-5$90.2M$9.4M$4.3M$6.1M
FQ-4$106.1M$9.9M$3.1M$539.8k
FQ-3$94.2M$8.7M$3.3M$4.5M
FQ-2
FQ-1$94.7M$2.3M-$1.3M
FQ0$96.1M$7.9M$179.8k-$18.3M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$261.9M$143.2M$9.4M
FQ-6$289.2M$151.6M$13.5M
FQ-5$335.9M$156.0M$23.1M
FQ-4$350.2M$159.1M$7.4M
FQ-3$350.1M$162.4M$5.3M
FQ-2
FQ-1$348.5M$162.1M$14.5M
FQ0$372.1M$162.3M$7.1M
PeriodOCFCapExFCFSBC
FQ-7-$3.5M-$2.7M$3.0M
FQ-6$2.6M-$5.3M$8.8M
FQ-5$264.4k-$6.5M$6.1M
FQ-4-$17.6M-$12.1M$539.8k
FQ-3-$5.5M-$2.0M$4.5M
FQ-2
FQ-1$14.6M-$10.5M
FQ0-$2.8M-$32.4M-$18.3M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$143.2M
Net cash-$68.2M
Current ratio1.6
Debt/Equity0.5
ROA1.1%
ROE1.9%
Cash conversion-1.2%
CapEx/Revenue-4.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
MetricRUBXActivity
Op margin9.7%5.5% medp25 -0.0% · p75 10.8%above median
Net margin4.8%4.1% medp25 0.1% · p75 8.8%above median
Gross margin25.2%20.5% medp25 12.4% · p75 29.7%above median
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-4.7%-6.2% medp25 -13.4% · p75 -2.6%above median
Debt / equity54.0%37.1% medp25 10.3% · p75 82.0%above median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-05 01:26 UTC#1f5bc239
Market quoteclose EGP 5.31 · shares 0.06B diluted
no public URL
2026-05-05 01:26 UTC#0338767e
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 06:38 UTCJob: e7d8b44e